p53 (149-157)

p53 (149-157) is a synthetic peptide fragment derived from the central region of the human tumor suppressor protein p53, specifically encompassing amino acids 149 to 157. As a highly conserved domain within the p53 sequence, this peptide segment plays a significant role in mediating protein-protein interactions, conformational stability, and post-translational modifications relevant to p53's regulatory functions. Researchers value this peptide for its utility in dissecting the structural and functional aspects of p53, a protein central to cell cycle control, DNA repair, and apoptosis. Its defined sequence and biochemical properties make it a versatile tool for in vitro studies, molecular interaction assays, and peptide-based screening applications.

Protein-Protein Interaction Studies: Investigators frequently employ the p53 (149-157) peptide to probe binding events between p53 and its regulatory partners, such as MDM2, MDMX, and other cellular modulators. By isolating this specific sequence, researchers can map interaction sites, determine binding affinities, and elucidate the molecular determinants of complex formation. These insights are critical for understanding the regulation of p53 activity and for identifying potential intervention points in the cellular stress response pathway.

Epitope Mapping and Antibody Validation: The defined sequence of the peptide serves as a reliable epitope for generating and validating antibodies against p53. In immunological assays, such as ELISA or Western blot, the peptide can be used as a positive control or as an antigen for screening the specificity and affinity of monoclonal or polyclonal antibodies. This application is vital for ensuring the accuracy of p53 detection in diverse biological samples and for supporting the development of high-quality immunoreagents.

Peptide-Based Inhibitor Screening: The p53 (149-157) fragment is instrumental in high-throughput screening platforms designed to identify small molecules or peptides that disrupt key p53 interactions. By mimicking the natural binding interface, the peptide enables researchers to assess the inhibitory potential of candidate compounds, facilitating the discovery of new modulators of p53 function. Such screening approaches are essential for advancing structure-activity relationship studies and for guiding the rational design of targeted inhibitors.

Structural and Biophysical Analysis: The peptide provides a tractable model for investigating the conformational dynamics and secondary structure of p53's central region. Through techniques such as NMR spectroscopy, circular dichroism, or crystallography, scientists can analyze how this segment folds, interacts with ligands, or undergoes conformational changes. These studies yield valuable data on the structural basis of p53 regulation and contribute to the broader understanding of tumor suppressor mechanisms at the molecular level.

Post-Translational Modification Research: The sequence spanning residues 149 to 157 includes sites susceptible to phosphorylation and other post-translational modifications that modulate p53 activity. Synthetic versions of the peptide, with or without specific modifications, enable detailed studies of kinase specificity, modification-dependent binding, and the functional consequences of site-specific changes. This application supports efforts to unravel the complex regulatory networks that govern p53's cellular roles and provides a foundation for further biochemical and signaling investigations.

1. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

2. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

3. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

4. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy